Altimmune, Inc. (ALT) Discusses Topline 48-Week Results From IMPACT Phase IIb Trial of Pemvidutide in MASH – Slideshow

Altimmune, Inc. (ALT) Discusses Topline 48-Week Results From IMPACT Phase IIb Trial of Pemvidutide in MASH – Slideshow#Altimmune #ALT #Discusses #Topline #48Week #Results #IMPACT #Phase #IIb #Trial #Pemvidutide #MASH #Slideshow